Greenlight Biosciences Holdings Pbc (GRNA) Return on Equity ROE from the first quarter 2023 to first quarter 2022 and annually, average high and low, overall ranking from Mar 31 2023 to Mar 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Greenlight Biosciences Holdings Pbc  (NASDAQ: GRNA)

Greenlight Biosciences Holdings Pbc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Greenlight Biosciences Holdings Pbc in the first quarter 2023?
Greenlight Biosciences Holdings Pbc recorded a cumulative net loss of $-157 million during 12 months ending in the first quarter 2023, resulting in a negative return on equity (ROE) of -374.26%.

Within the Biotechnology & Pharmaceuticals industry 132 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2022 from 0 to 4139.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter
Y / Y Equity Change -65.63 % - 2034.39 % -57.5 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -157 -167 -163 -154 -129
Return On Equity (TTM) -374.26 % -318.16 % -493.86 % -1195.29 % -737.44 %
GRNA's Total Ranking # 4139 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 22 48 84 14 64
Seq. Equity Change -54.36 % -43.06 % 515.05 % -78.5 % -
Seq. Net Income Change - - - - -

Back to GRNA Management Effectiveness >> GRNA's 5 Years Annual ROE >> Compare GRNA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 133
Sector # 873
Overall # 4139

Return On Equity Statistics
High Average Low
-257.61 %
-493.37 %
-1031.61 %
(Jun 30 2021)   (Jun 30 2022)





GRNA Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021


Total Equity in Millions 48 -28 80 0 0
Y / Y Equity Change - - - - -
Net Income in Millions -167 -15 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity -347.58 % - - - -

Back to GRNA Management Effectiveness >> GRNA's 5 Years Annual ROE >> Compare GRNA ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GRNA's' Return on Equity at Yahoo Finance
GRNA's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GRNA's Competitors
Subscribers only: Roe for Greenlight Biosciences Holdings Pbc's Suppliers
Subscribers only: Return On Equity for GRNA's Customers




Companies with similar Return On Equity at Mar 31 2023, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.